Hostname: page-component-7c8c6479df-ws8qp Total loading time: 0 Render date: 2024-03-28T12:09:53.789Z Has data issue: false hasContentIssue false

Quetiapine immediate release v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal

Published online by Cambridge University Press:  02 January 2018

Paul Hutton*
Affiliation:
Department of Clinical Psychology, School of Health in Social Science, University of Edinburgh
Peter J. Taylor
Affiliation:
Department of Clinical Psychology, Institute of Psychology, Health and Society, University of Liverpool
Lee Mulligan
Affiliation:
Department of Clinical Psychology, School of Psychological Sciences, University of Manchester
Sarah Tully
Affiliation:
Psychosis Research Unit, Greater Manchester West Mental Health Foundation National Health Service Trust, Manchester
Joanna Moncrieff
Affiliation:
Mental Health Sciences Unit, School of Life and Medical Sciences, University College London, UK
*
Dr Paul Hutton, Department of Clinical Psychology, Doorway 6, Medical Building, Teviot Place, Edinburgh EH8 9AG, UK. Email: paul.hutton.cf@ed.ac.uk.
Rights & Permissions [Opens in a new window]

Abstract

Background

Immediate-release (IR) quetiapine has been used to treat schizophrenia since 1997, although all the principal placebo-controlled trials have >50% missing outcome data. New studies with relatively lower rates of participant withdrawal have since been published.

Aims

To assess the efficacy and adverse effects of quetiapine IR for schizophrenia, with consideration of outcome quality and clinical meaningfulness of results, and to examine the potential impact of missing data on the main efficacy findings.

Method

We conducted a systematic review and meta-analysis of randomised controlled trials comparing quetiapine IR and placebo (or subtherapeutic dose in relapse prevention trials) for the treatment of schizophrenia (PROSPERO registration CRD4201100165). Primary outcomes were change in overall symptoms and response rates. We also examined whether high rates of participant withdrawal (⩾50%) attenuated effect sizes, and assessed the impact of making different assumptions about these people's outcomes.

Results

We identified 15 relevant trials (including 2 unpublished), providing the first 12-week data for this drug and the first data on self-reported quality of life. We found quetiapine IR to have a weighted mean difference (WMD) of 6.5 points (95% CI −8.9 to −4) on Positive and Negative Syndrome Scale (PANSS) total scores, which corresponds to a standardised mean difference (SMD) of −0.33 (95% CI −0.46 to −0.21). Longer trials reported larger mean differences favouring quetiapine IR, but the overall estimate was smaller if more conservative assumptions about the outcomes of people who left the trial early were made. Approximately 21 people needed to take quetiapine IR for 1 person to experience at least a 50% improvement in PANSS score. No difference in quality of life was observed (two RCTs), although small to moderate improvements in social functioning were found (three RCTs). Quetiapine IR caused sedation and increased rates of clinically significant weight gain, but no extrapyramidal effects were observed.

Conclusions

Quetiapine IR has a small beneficial effect on overall psychotic symptoms over 2–12 weeks, but also leads to weight gain and sedation.

Type
Review article
Copyright
Copyright © Royal College of Psychiatrists, 2015 

Quetiapine is a widely prescribed antipsychotic. 1 First manufactured by AstraZeneca, it was initially introduced for the treatment of schizophrenia and non-affective psychosis in the late 1990s, but is now licensed in several countries for the treatment of bipolar disorder and other conditions. The original immediate-release (IR) version was the third most frequently prescribed antipsychotic in the UK from 2004 to 2007, and by 2008 had been taken by over 25 million people worldwide. 2 The patent for quetiapine IR expired in March 2012 and the generic version is now comparable in cost to haloperidol, leading to considerable cost savings. Although older reviews of comparative and placebo-controlled trials concluded it was an effective treatment for schizophrenia and non-affective psychosis, Reference Srisurapanont, Maneeton and Maneeton3,Reference Leucht, Arbter, Engel, Kissling and Davis4 these were based on a limited number of trials which suffered from severe attrition. The Cochrane review, for example, noted that most of the original placebo-controlled studies were severely compromised by missing outcome data, and that their results were therefore ‘impossible to interpret with confidence’. Reference Srisurapanont, Maneeton and Maneeton3 Three of the four included studies were missing more than half of their 6-week outcome data, and the remaining study had only 12 participants. In each case the outcomes of those leaving early were estimated by the method of carrying their last available observation forward, an imputation strategy now regarded as unreliable. Reference Hamer and Simpson5 In their 2009 review Leucht et al found that, overall, second-generation antipsychotics had a moderate effect on symptoms (Hedges’ g= 0.51). Reference Leucht, Arbter, Engel, Kissling and Davis4 However, they suggested that the high withdrawal rate in these studies might have attenuated the drug-placebo difference. Indeed, in most placebo-controlled trials more than a quarter of participants leave the study, and in a significant number of trials more than half do so. Reference Hutton, Morrison, Yung, Taylor, French and Dunn6 Such high rates of missing data cannot be safely ignored. A recent survey by the Cochrane Schizophrenia Group found consultant psychiatrists, patients, carers and Cochrane researchers in agreement that trials with over 25% missing data lack credibility, Reference Xia, Adams, Bhagat, Bhagat, Bhoopathi and El-Sayeh7 and there is largely a consensus that no statistical approach can produce reliable results when assumptions about the outcomes of participants carry more weight than actual observations. Reference Xia, Adams, Bhagat, Bhagat, Bhoopathi and El-Sayeh7,Reference Leucht, Heres, Hamann and Kane8 Understanding the impact of missing data is particularly challenging if it is missing for non-random reasons that are related to outcome, as may be the case for antipsychotic trials. Reference Rabinowitz and Davidov9 The development of a sustained release version of quetiapine (quetiapine XR) has led to new randomised controlled trials (RCTs) comparing the immediate release version with placebo, some of which had relatively low rates of missing data. Owing to the uncertainty introduced by high attrition in the older studies of quetiapine IR, we set out to perform a new systematic review and meta-analysis.

We had two main objectives. The first was to provide a comprehensive assessment of the efficacy and adverse effects of quetiapine IR for schizophrenia when compared with placebo, with consideration of both outcome quality and the clinical meaningfulness of the results, as informed by recent advances in our understanding of what constitutes a minimum clinically important difference in Positive and Negative Syndrome Scale (PANSS) total scores. Reference Leucht, Kane, Etschel, Kissling, Hamann and Engel10Reference Hermes, Sokoloff, Stroup and Rosenheck12 Our second objective was to examine the potential impact of missing data on the primary outcomes. More specifically, we examined whether trials with high rates of missing data had smaller effect sizes, Reference Leucht, Arbter, Engel, Kissling and Davis4 and we used a recently published approach to examine the impact on our efficacy estimates of changing assumptions about the likely outcomes of the large numbers of people who leave these trials early. Reference Ebrahim, Akl, Mustafa, Sun, Walter and Heels-Ansdell13

Method

Our search strategy and protocol detailing our inclusion and exclusion criteria are provided in an online data supplement. Two researchers independently searched publication databases, clinical trial registries and previous reviews for randomised controlled trials in which participants with a diagnosis of schizophrenia or early psychosis were randomly allocated to receive double-blind treatment with either placebo or quetiapine IR. No pre-specified limits were placed on study duration.

Data extraction and outcomes

Two reviewers independently extracted data from each study using data extraction forms. We attempted to trace missing summary data by contacting first authors or the study sponsor. Our primary outcomes were the average reduction at study end-point in total score on the PANSS or, if that were not available, on the Brief Psychiatric Rating Scale (BPRS), and the numbers of people achieving an important clinical response. We defined the latter as a greater than 50% reduction in PANSS or BPRS score. Reference Leucht, Kane, Kissling, Hamann, Etschel and Engel14 When these were not reported or provided, we imputed them from means and standard deviations using the validated method of Furukawa et al. Reference Furukawa, Cipriani, Barbui, Brambilla and Watanabe15 (See ‘Changes from protocol’ section in the online supplement.) Our secondary efficacy outcomes included relapse, positive symptoms, negative symptoms, depression, quality of life and need for additional antipsychotic medication or sedatives. We also examined the numbers of participants leaving the study early for any reason, need for hospital care and functioning. For adverse effects, we looked at use of anti-Parkinsonian medication, extrapyramidal side-effects, withdrawal due to adverse events, sedation, total number of drug-attributable adverse events, insomnia, weight gain and weight loss.

We used a strict intention-to-treat (ITT) analysis for dichotomous outcomes, using the total numbers randomised to each group as the denominator in each case. Where possible, we assumed those leaving early or otherwise unaccounted for had an unchanged outcome from randomisation, but carried out sensitivity analyses to test this. Data incorporating last observation carried forward (LOCF) assumptions were used only when there was no alternative. We also wished to use a strict ITT analysis for continuous data, but expected to be limited to summary data derived from smaller samples excluding participants leaving the study early or those without at least one post-baseline assessment. For all outcomes we intended to use summary data based on the mixed-model repeated measures (MMRM) imputation method, followed by LOCF or observed case data if not available. Missing standard deviations were, where possible, calculated from t-test values, P-values, standard errors or confidence intervals. Reference Higgins and Green16 If no variance parameters were reported for a particular study, we imputed standard deviations using the medians of the other studies. Similarly to previous studies, Reference Leucht, Arbter, Engel, Kissling and Davis4,Reference Leucht, Corves, Arbter, Engel, Li and Davis17 we planned to use data from study arms where participants received an optimal drug dose of more than 250 mg. However, we carried out a sensitivity analysis excluding doses of more than 400 mg, as per the recent International Consensus on Antipsychotic Dosing and recent Leucht group analysis. Reference Gardner, Murphy, O'Donnell, Centorrino and Baldessarini18,Reference Leucht, Cipriani, Spineli, Mavridis, Orey and Richter19

Meta-analytic calculations

For continuous data we calculated the Hedges’ g standardised mean difference (SMD) using Comprehensive Meta-Analysis version 2 for Windows 7. For the primary analysis of the 2–12 week study end-point data we converted BPRS scores (mean and s.d.) to PANSS scores using recently published conversion charts (PANSS total score = 1.538 × BPRS total score), Reference Leucht, Rothe, Davis and Engel20 thus allowing us to present also the unstandardised weighted mean difference (WMD) in PANSS total scores for all the studies combined. When a trial had two or more relevant arms we combined the data following procedures in the Cochrane Handbook. Reference Higgins and Green16 For binary data we calculated the relative risk (RR) of the unfavourable outcome, together with 95% confidence intervals, as well as the absolute risk difference and numbers needed to treat (NNT) or harm (NNH). If a trial had eligible binary data from two or more active treatment arms, we combined these into one. We used a random effects analysis for all outcomes. For the primary outcomes we also performed a sensitivity analysis using fixed effects, but not if heterogeneity was moderate or more, defined as an I 2 statistic of ≥40%. Reference Higgins and Green16

Impact of missing data

We tested the hypothesis that trials with severe rates of missing data (≥50% at end-point) had smaller drug-placebo differences on our primary outcomes than trials with less severe rates (<50%). The 50% cut-off was chosen because it marks the point at which estimated data carry more weight than actual observations, and because the National Institute for Health and Care Excellence (NICE), the Cochrane Schizophrenia Group and others often exclude trials with this degree of missing data from their reviews. Reference Hutton, Morrison, Yung, Taylor, French and Dunn6,21,Reference Bagnall, Jones, Ginnelly, Lewis, Glanville and Gilbody22 We also wished to compare studies with <25% and ≥25% attrition at end-point, Reference Xia, Adams, Bhagat, Bhagat, Bhoopathi and El-Sayeh7 but were unable to do so because no study of 6–12 weeks’ duration had less than 25% attrition. When observed case data were available we were also able to examine the impact of missing data on the primary outcome by imputing values for those who left the trial early using new guidelines provided by Ebrahim et al. Reference Ebrahim, Akl, Mustafa, Sun, Walter and Heels-Ansdell13 Their method involves testing whether the overall treatment effect is robust under four increasingly more conservative strategies – two of which we applied here. Strategy 1 is non-extreme and involves replacing missing data in both arms of each trial with the observed case mean of the control arm. Strategy 2 is more conservative yet plausible, and uses the highest observed control arm mean to replace missing control arm data, and the lowest observed intervention arm mean to replace missing intervention arm data. For both approaches we imputed the missing data treatment and placebo standard deviations with the medians of the control arms of all the included trials, as recommended. Reference Ebrahim, Akl, Mustafa, Sun, Walter and Heels-Ansdell13

Analysis of clinical significance

The minimum clinically important difference (MCID) has been defined by Jaeschke et al as ‘the smallest difference in a score in the domain of interest which patients [or providers] perceive as beneficial and which would mandate in the absence of troublesome side-effects and excessive cost, a meaningful change in the patient’s management’. Reference Thwin, Hermes, Lew, Barnett, Liang and Valley11,Reference Jaeschke, Singer and Guyatt23 An analysis of data from 14 antipsychotic trials (n = 5970) found a rater-determined MCID on the PANSS of roughly 15 points, Reference Leucht, Kane, Etschel, Kissling, Hamann and Engel10 a criterion that has since been replicated by separate analyses of two large non-industry effectiveness trials (n = 1650). Reference Thwin, Hermes, Lew, Barnett, Liang and Valley11,Reference Hermes, Sokoloff, Stroup and Rosenheck12 Data from a large naturalistic study (n = 398) suggested a lower criterion of 10 points, Reference Schennach-Wolff, Obermeier, Seemuller, Jager, Schmauss and Laux24 which is similar to the patient-rated MCID of 11 points derived from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Reference Hermes, Sokoloff, Stroup and Rosenheck12 We tested the validity of these definitions by comparing them with the median of mean changes that the included trials were designed to detect. We assumed that trial sponsors had provided enough resources to detect with adequate power what they regarded a priori as the smallest difference between the groups that was important to detect. Reference Man-Son-Hing, Laupacis, O'Rourke, Molnar, Mahon and Chan25

Risk of bias and study quality

Two raters independently assessed both study-level risk of bias with the Cochrane Collaboration risk of bias tool, Reference Higgins and Green16 and outcome quality using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Reference Guyatt, Oxman, Vist, Kunz, Falck-Ytter and Alonso-Coello26 Further details on method and ratings are provided in the online supplement. We tested for publication bias using funnel plots for the PANSS/BPRS total score effect sizes (Hedges’ g) of all studies. Ratings of bias and quality were used to inform interpretation of reliability and magnitude of effects.

Registration of review protocol and subsequent changes

The review protocol was registered in advance with the International Prospective Register of Systematic Reviews (PROSPERO), protocol CRD4201100165. Subsequent changes, in addition to those outlined above, are detailed in the online supplement. We abandoned the use of the response rate hierarchy used by Leucht et al, Reference Leucht, Arbter, Engel, Kissling and Davis4 given their recently expressed concerns that response rate estimates are particularly vulnerable to selective reporting bias, Reference Leucht, Cipriani, Spineli, Mavridis, Orey and Richter19 and used only the top of the hierarchy instead (50% or more reduction in PANSS/BPRS score). This criterion is now recommended for use in studies of acutely ill patients with nonrefractory illness, Reference Leucht, Davis, Engel, Kissling and Kane27 and we used the method of Furukawa et al to impute this data when not reported or provided. Reference Furukawa, Cipriani, Barbui, Brambilla and Watanabe15 This method has been recently validated using individual patient-level data from 16 antipsychotic trials, Reference Samara, Spineli, Furukawa, Engel, Davis and Salanti28 and has the additional advantage of allowing for the use of adjusted PANSS and BPRS total scores when calculating percentage change, thus avoiding underestimation of response. Reference Leucht, Davis, Engel, Kissling and Kane27 Additional changes included using meta-regression to assess the association between study duration (measured in weeks) and year of publication on total symptoms and clinically significant improvement. These were conducted in Stata version 9 using the Metareg command and Knapp-Hartung variance estimator. Reference Harbord and Higgins29

Results

The process of selecting studies is detailed in Fig. 1. We identified 15 relevant trials, 11 of which assessed short-term efficacy (n = 2259). Lundbeck provided us with summary reports for two unpublished 12-week placebo-controlled studies, 30,31 both of which were terminated early owing to the inefficacy of the investigational drug (bifeprunox; quetiapine IR was an active comparator in these trials). AstraZeneca, the makers of quetiapine, provided us with a considerable amount of additional unpublished data in relation to many of their trials. They decided not to provide us with the report for one unpublished long-term trial comparing therapeutic and subtherapeutic doses of quetiapine, Reference Arvanitis and Scott32 arguing that the lack of a placebo control meant it did not meet our original inclusion criteria. However, we managed to acquire an extract detailing the main results, and other published summaries allowed us partly to assess risk of bias. We therefore included data from a total of 15 studies. An overview of included studies is provided in Table 1, and excluded studies are listed in the online supplement, together with a table of trial characteristics and baseline demographic data.

Fig. 1 Study search procedure. IR, immediate release; RCT, randomised controlled trial.

Table 1 Included studies and Cochrane risk of bias ratings

Year
published/
completed
Primary
publication
available?
Clinical
study report
synopsis
or extract
available?
Random
sequence
generation
(selection
bias)
Allocation
concealment
(selection
bias)
Performance
bias
(masking of
participants
and
personnel)
Detection
bias
(masking
of
assessments)
Incomplete
outcome
data
(attrition
bias)
Selective
reporting
(reporting
bias)
Other
biasFootnote a
Arvanitis & Miller 1997 Yes Reference Arvanitis and Miller38 YesFootnote b Unclear Unclear Unclear Unclear High Unclear High
Small et al 1997 Yes Reference Small, Hirsch, Arvanitis, Miller and Link41 YesFootnote b Low Unclear Unclear Unclear High Unclear High
Borison et al 1996 Yes Reference Borison, Arvanitis and Miller42 YesFootnote b Unclear Unclear Unclear Unclear High High High
Kahn et al 2007 Yes Reference Kahn, Schulz, Palazov, Reyes, Brecher and Svensson43 Yes Unclear Unclear Unclear Unclear High High Unclear
Canuso et al 2009 Yes Reference Canuso, Dirks, Carothers, Kosik-Gonzalez, Bossie and Zhu37 YesFootnote c Low Low Unclear Unclear Low Unclear Unclear
Potkin et al 2006 Yes Reference Potkin, Gharabawi, Greenspan, Mahmoud, Kosik-Gonzalez and Rupnow36 No Low Low Unclear Unclear Low High Unclear
Chen et al 2010 Yes Reference Chen, Hui, Lam, Chiu, Law and Chung45 No Low Low Unclear Unclear High High High
Lindenmayer et al 2008 Yes Reference Lindenmayer, Brown, Liu, Brecher and Meulien39 Yes Unclear Unclear Unclear Unclear High High Unclear
Cutler et al 2010 Yes Reference Cutler, Tran-Johnson, Kalali, Astrom, Brecher and Meulien44 Yes Unclear Unclear Unclear Unclear High High Unclear
Hough et al 2011 Yes Reference Hough, Natarajan, Vandebosch, Rossenu, Kramer and Eerdekens51 Yes Low Low Unclear High Low High Unclear
Chapel et al 2009 Yes Reference Chapel, Hutmacher, Haig, Bockbrader, de Greef and Preskorn52 No Unclear Unclear Unclear High Unclear High Unclear
Findling et al 2012 Yes Reference Findling, McKenna, Earley, Stankowski and Pathak40 Yes Low Low Unclear Unclear High Low Low
Study 11915A 2009 No Yes 30 Unclear Unclear Unclear Unclear High High High
Study 11916A 2009 No Yes 31 Unclear Unclear Unclear Unclear High High High
Arvanitis & Scott
(Study 15)
1995 No Partially Reference Arvanitis and Scott32 Unclear Unclear Low Low High High High

a. Not including financial conflict of interest of sponsor or researcher.

b. AstraZeneca supplied extract.

c. Pfizer supplied extract.

Risk of bias and quality ratings

Table 1 provides the main risk of bias ratings, and the right-hand columns of Tables 2 and 3 provide the outcome quality ratings for the main primary and safety outcomes. Ratings for secondary outcomes and additional safety outcomes are provided in the online supplement. Our rationale for the ratings is also provided online, alongside ratings produced by other research groups (where available). In our judgement the main problem with these trials is a somewhat high risk of selective reporting bias in relation to secondary outcomes and adverse effects, coupled with a very high risk of attrition bias for most outcomes. We also judge unblinding due to sedative effects to be likely, Reference Perlis, Ostacher, Fava, Nierenberg, Sachs and Rosenbaum33 and the double-blind design might not protect against the risk of researchers adopting a high threshold for recording effects (e.g. adverse effects) where the desired outcome is ‘no difference’. Reference Treadwell, Uhl, Tipton, Shamliyan, Viswanathan and Berkman34 There is also evidence from documents released through legal proceedings in the USA that AstraZeneca have historically not published all

Table 2 Primary efficacy outcomes

Outcome Time
(weeks)
No. of
included
studies
Quetiapine
n events/n
Placebo
n events/n
Hedges’ g
(95% CI)
Difference
Mean (95% CI)
Risk ratio
(95% CI)
Absolute
difference
(95% CI)
NNTB/H
(95% CI)
Heterogeneity
for g or RR
Quality
(GRADE)
Overall symptoms (mean change in PANSS
total score) based on LOCF or MMRM
2–12 11 1346 912 –0.33 (–0.44, –0.21)Footnote * –6.44 (–8.89, –4.00)Footnote * I 2 = 47%; χ2 = 18.9
(P = 0.040)
Moderate
to high
Overall symptoms (mean change In PANSS
total score) using strategy 1 imputations
2–12 11 1373 931 –0.23 (–0.35, –0.11)Footnote * –4.25 (–6.46, –2.04)Footnote * I 2 = 52%; χ2 = 20.7
(P = 0.023)
Overall symptoms (mean change In PANSS
total score) using strategy 2 Imputations
2–12 11 1373 931 –0.15 (–0.30, 0.01) –2.66 (–5.46, 0.15) I 2 = 70%; χ2 = 32.9
(P < 0.001)
Significant Improvement (≥50% reduction
in PANSS/BPRS score) based on LOCF
2–12 11 1126/1375 816/933 0.95
(0.91, 0.98)Footnote *
–0.047
(–0.016, –0.016)Footnote *
21B
(13B, 63B)Footnote *
I 2 = 43%; χ2 = 17.5
(P = 0.070)
Low to
moderate

BPRS, Brief Psychiatric Rating Scale; LOCF, last observation carried forward; MMRM, mixed-models repeated measures; NNTB/H, number needed to treat (benefit/harm); PANSS, Positive and Negative Syndrome Scale; RR, relative risk.

* P < 0.05.

active-comparator quetiapine trials, or have not reported all outcomes. Reference Spielmans and Parry35

Validation of MCID criterion

Researchers and trial sponsors designed their trials to detect with adequate power a mean change in PANSS total score or equivalent of approximately 12 points (range 9.0–15.5), which corresponds to an SMD of 0.55, and is similar in magnitude to the empirically derived estimate of MCID of 11–15 points. Reference Leucht, Kane, Etschel, Kissling, Hamann and Engel10Reference Hermes, Sokoloff, Stroup and Rosenheck12

Primary efficacy outcomes

Moderate- to high-quality evidence suggested that quetiapine IR was statistically superior to placebo from 2 weeks to 12 weeks in terms of reducing overall symptoms, but the effect was small (WMD = –6.5 points, 95% CI –8.89 to –4.00; SMD = –0.33, 95% CI –0.46 to –0.21) and the 95% confidence intervals excluded the MCID of 11–15 points (Table 2, Figs 2 and 3). Low- to moderate-quality evidence suggested the NNT for much improvement was 21 (95% CI 13 to 63).

Fig. 2 Mean change in Positive and Negative Syndrome Scale (PANSS) total scores or equivalent, using mostly original last observation carried forward estimates to impute missing data. PLA, placebo; QUE, quetiapine. *Severe attrition (≥50%).

Fig. 3 Relative risk of not achieving at least 50% reduction in Positive and Negative Syndrome Scale (PANSS) total scores or equivalent, based mostly on last observation carried forward data; F estimated using Furukawa method. PLA, placebo; QUE, quetiapine. *Severe attrition (≥50%).

Sensitivity analyses and meta-regression

We identified a significant effect of study duration (weeks) on the effect size for total PANSS score (B = –0.04, 95% CI –0.08 to –0.01; P = 0.02), with a more treatment-favourable outcome associated with longer duration. Treatment duration did not significantly moderate the effect for treatment response (B< –0.01, RR = 1.00, 95% CI 0.98 to 1.01; P = 0.70). Excluding the two 2-week studies (Potkin et al, Canuso et al) was associated with a marginal increase in average PANSS change (WMD = –7.7 points, 95% CI –10.0 to –5.3; SMD = –0.38, 95% CI –0.50 to –0.26) and response rates (NNT = 19, 95% CI 11 to 59). Reference Potkin, Gharabawi, Greenspan, Mahmoud, Kosik-Gonzalez and Rupnow36,Reference Canuso, Dirks, Carothers, Kosik-Gonzalez, Bossie and Zhu37 Year of publication did not significantly predict outcomes for total PANSS (B = 0.01, 95% CI –0.01 to 0.04; P = 0.28), but there was a small association for treatment response (B = 0.01, RR = 1.01, 95% CI 1.00 to 1.02; P = 0.01), with a less treatment-favourable outcome associated with a more recent publication date. Meta-regression bubble plots are provided in the online supplement.

Removing data from arms employing doses smaller than 400 mg reduced the contribution made by two trials, Reference Arvanitis and Miller38,Reference Lindenmayer, Brown, Liu, Brecher and Meulien39 but this had little effect on the overall estimate of average change (WMD = –6.3, 95% CI –8.7 to –3.8; SMD = –0.32, 95% CI –0.44 to –0.20) or response rates (NNT = 20, 95% CI 13 to 53). Excluding the study with an adolescent sample (Findling et al) also had little effect on estimates (WMD = –6.3, 95% CI –8.9 to –3.6; SMD = –0.32, 95% CI –0.45 to –0.19; NNT = 22, 95% CI 13 to 83). Reference Findling, McKenna, Earley, Stankowski and Pathak40

Impact of missing data

Overall, the seven 2–12 week trials with less than 50% attrition had a mean PANSS advantage of –5.4 points (95% CI –8.0 to –2.9; SMD = –0.29, 95% CI –0.44 to –0.15) and an NNT of 42 (19, 250H; H = harm), whereas the four 6-week studies with 50% or more attrition had a mean PANSS advantage of 9.2 points (95% CI –15 to –3.4; SMD = –0.39, 95% CI –0.62 to –0.17) and an NNT of 13 (95% CI 7 to 250). The three 6-week studies with less than 50% attrition had a mean advantage of 6.1 points (95% CI –9.9 to –2.3; SMD = –0.27, 95% CI –0.43 to –0.12) and a non-significant NNT of 35 (95% CI 12 to 42H).

Strategy 1 of the Ebrahim approach involved testing whether the overall results would be different if we assumed that participants who withdrew early from both groups had the same degree of change as participants in the control group who stayed until the end. Reference Ebrahim, Akl, Mustafa, Sun, Walter and Heels-Ansdell13 To illustrate this, consider the study by Small et al. Reference Small, Hirsch, Arvanitis, Miller and Link41 Here the mean change for the 49 quetiapine and 39 placebo group participants who completed the trial was, after conversion of BPRS to PANSS scores, –23.3 points (s.d. = 17.7) and –14.9 points (s.d. = 17.7) respectively – a between-group difference of around 8.4 points. Carrying forward the last available scores of the 104 people who did not complete this trial reduced the quetiapine estimate to –13.5 points (s.d. = 24.5; n = 94) and the placebo estimate to –1.5 points (s.d. = 24.0; n = 94), and increased the

between-group difference to around 12 points. These are the figures we used in the main analysis. Introducing the strategy 1 assumption that those who did not complete the trial had a similar outcome to those in the placebo group who did complete it (–14.9 points) reduced the overall estimate for the quetiapine group to –19.1 points (s.d. = 18.2) and reduced the advantage over placebo to 4.2 points. We repeated this procedure for the other five trials for which we had completer data and where no usable MMRM estimate was provided, Reference Arvanitis and Miller38,Reference Lindenmayer, Brown, Liu, Brecher and Meulien39,Reference Borison, Arvanitis and Miller42Reference Cutler, Tran-Johnson, Kalali, Astrom, Brecher and Meulien44 and entered the revised estimates into the overall meta-analysis. Table 2 shows that the overall advantage for quetiapine over placebo fell to 4.3 points (95% CI –6.5 to –2.0; SMD = –0.23, 95% CI –0.35 to –0.11).

Strategy 2 of the Ebrahim approach involved testing whether the overall results were robust to assuming, first, that participants in the quetiapine non-completers group had the smallest treatment response observed, and second, that those in the placebo non-completers group had the largest placebo response observed. In the study by Small et al this involved assuming the 47 people in the quetiapine non-completers group had the same degree of response as the quetiapine completers group in the study by Lindenmayer et al (–17.4 points), Reference Lindenmayer, Brown, Liu, Brecher and Meulien39 and that the 57 people in the placebo non-completers group had the same degree of response as the placebo completers group in the 2007 study by Kahn et al (–23.1 points). Reference Kahn, Schulz, Palazov, Reyes, Brecher and Svensson43 The revised quetiapine and placebo estimates were –20.4 (s.d. = 18.2) and –19.8 points (s.d. = 18.3) respectively, leading to a between-group difference of 0.6 points. As shown in Table 2, applying strategy 2 to the six trials for which we had completer data reduced the overall advantage for quetiapine to 2.7 points (95% CI –5.5 to 0.2; SMD = –0.15, 95% CI –0.30 to 0.01). Revised forest plots for strategies 1 and 2 are provided in the online supplement.

Publication bias

We detected some asymmetry in the funnel plot of clinically significant change, but not in relation to mean change in overall symptoms or most other outcomes. Funnel plots for the primary outcomes are provided in the online supplement.

Secondary efficacy outcomes

Full details concerning secondary efficacy outcomes are given in sections H and K of the online supplement.

Relapse, exacerbation and need for hospital care

Evidence from one study indicated that quetiapine IR was effective for prevention of symptom exacerbation in people with early psychosis who had responded to quetiapine, Reference Chen, Hui, Lam, Chiu, Law and Chung45 but an unpublished study suggested there was no effect of therapeutic dose (300–600 mg) over a subtherapeutic dose (75 mg) in relapse prevention in chronic schizophrenia. Reference Arvanitis and Scott32 The combined estimate was therefore heterogeneous (I 2 = 87%) and not significant (NNT = 5, 95% CI 2 to 13H). Quetiapine IR was associated with a marginally reduced need for hospital care after 2–6 weeks in three RCTs (NNT = 19, 95% CI 10 to 143). Reference Potkin, Gharabawi, Greenspan, Mahmoud, Kosik-Gonzalez and Rupnow36,Reference Canuso, Dirks, Carothers, Kosik-Gonzalez, Bossie and Zhu37,Reference Cutler, Tran-Johnson, Kalali, Astrom, Brecher and Meulien44 One trial suggested quetiapine IR had a small effect over 52 weeks in relation to reducing readmission to hospital due to relapse (NNT = 11, 95% CI 6 to 143), Reference Chen, Hui, Lam, Chiu, Law and Chung45 but the results were not robust to changing assumptions about the outcome of those leaving early. Overall the relapse and readmission data were very low to low in quality.

Other outcomes

There was a small effect on positive symptoms (SMD = –0.32, 95% CI –0.44 to –0.20; moderate-quality evidence) and a marginal to small effect on negative symptoms (SMD = –0.21, 95% CI –0.32 to –0.10; moderate-quality evidence) over 2–12 weeks, and a marginal effect on depression over 2–6 weeks (SMD = –0.13, 95% CI –0.23 to –0.02; low-quality evidence). Forest plots are provided in the online supplement. We did not investigate whether these estimates were robust to missing data, but the sensitivity analyses for the primary outcome of total symptoms suggest that this is unlikely. Those taking quetiapine IR had a marginally reduced need for additional sedative medication after 2–6 weeks (NNT = 34, 95% CI 13 to 53H; six RCTs), but we judged the evidence as low quality because of selective reporting and missing data, and no reduced need for antipsychotic medication was observed in the two 6-week RCTs where additional medication was not restricted (NNT = 24, 95% CI 7 to 19H; moderate-quality evidence). Reference Potkin, Gharabawi, Greenspan, Mahmoud, Kosik-Gonzalez and Rupnow36,Reference Canuso, Dirks, Carothers, Kosik-Gonzalez, Bossie and Zhu37

Pooled self-report end-point data from the two 12-week trials did not indicate any benefit of quetiapine IR on quality of life, 30,31 as measured by the Schizophrenia Quality of Life (S-QoL) scale (SMD = 0.11, 95% CI –0.15 to 0.36), but we judged the evidence to be very low in quality owing to early termination of the trials, missing data and possible selective reporting from the other trials. No significant effect was observed on any of the subscales, including psychological well-being (SMD = –0.02, 95% CI –0.28 to 0.24) or family relationships (SMD = 0.01, 95% CI –0.25 to 0.28). Since only observed case S-QoL data were reported, we imputed missing data using strategy 1 from Ebrahim et al. Reference Ebrahim, Akl, Mustafa, Sun, Walter and Heels-Ansdell13 This reduced the overall effect from 0.11 to 0.06 (95% CI –0.14 to 0.27). Long-term quality of life data from two RCTs remain unpublished. Reference Arvanitis and Scott32,Reference Chen, Hui, Lam, Chiu, Law and Chung45

An analysis of data from three RCTs (one studying adolescents, two with adult samples) covering a period of 6–12 weeks found quetiapine IR had a small to moderate benefit on functioning, 30,31,Reference Findling, McKenna, Earley, Stankowski and Pathak40 as assessed by a combination of Children’s Global Assessment Scale data and Personal and Social Performance (PSP) data (SMD = 0.39, 95% CI 0.18 to 0.60). Global Assessment of Functioning data were also reported, but unlike the PSP this measure assesses symptom severity as well as functioning. After imputing missing PSP data using strategy 1, the effect size was small (SMD = 0.28, 95% CI 0.09 to 0.46). One study found no benefit of 12 months of quetiapine IR maintenance treatment over placebo in relation to employment status. Reference Chen, Hui, Lam, Chiu, Law and Chung45 Overall, the functioning and employment data were very low in quality owing to selective reporting, early termination of studies, imprecision and missing data. High-quality evidence from 11 trials suggested quetiapine IR had a marginal effect on rates of early discontinuation over a period of 2–6 weeks (NNT = 21, 95% CI 10 to 333H).

Safety outcomes

Safety outcomes are detailed in Table 3 and Figs 4, 5, 6. There was low-quality evidence that quetiapine IR was associated with a small to moderately increased risk of non-serious adverse effects over the short term (NNH = 11, 95% CI 8 to 22). There was no evidence of extrapyramidal side-effects and no evidence of an increased risk of serious adverse events. Moderate-quality evidence suggested no need for additional anti-Parkinsonian medication in quetiapine-treated participants in the short term, but longer-term data were not reported. Data from 12 trials suggested quetiapine IR had a moderate to large effect on weight gain over 2–12 weeks (SMD = 0.64, 95% CI 0.43 to 0.85). Participants gained an extra 1.75 kg (95% CI 1.10 to 2.40) on average, but we rated the evidence as very low quality because of non-reporting of variance parameters in 7 out of 12 studies, high rates of withdrawal and high heterogeneity. Moderate-quality evidence suggested that around 12% of participants treated with quetiapine experienced a clinically significant increase in weight over 2–12 weeks, compared with 4% of those taking placebo (NNH = 13, 95% CI 9 to 23), and 35% reported sedation or somnolence as an adverse effect compared with 6% of those taking placebo (NNH = 9, 95% CI 7 to 13). Details on additional safety outcomes and forest plots are reported in sections I and K of the online supplement.

Table 3 Main safety outcomes

Outcome
(definition, imputation strategy)
Time
(weeks)
No. of
included
studies
Quetiapine
n events/n
Placebo
n events/n
Hedges’ g
(95% CI)
Difference
Mean
(95% CI)
Risk ratio
(95% CI)
Absolute
difference (95% CI)
NNTB/H
(95% CI)
Heterogeneity
for g or RR
Quality
(GRADE)
Serious adverse event 2–12 8 50/851 45/658 0.94 (0.64, 1.39) –0.001 (–0.023, 0.021) 1000B (44B, 48H) I 2 = 47%; χ2 = 3.3
(P = 0.885)
Very low
Any adverse event 2–12 9 754/1112 438/756 1.14 (1.06, 1.22)Footnote * 0.089 (0.045, 0.134)Footnote * 11H (22H, 8H)Footnote * I 2 = 0%; χ2 = 6.6
(P = 0.583)
Low
Simpson–Angus Scale (worsening) 6 7 128/869 83/596 0.97 (0.73, 1.29) 0.007 (–0.033, 0.047) 143H (30B, 21H) I 2 = 15%; χ2 = 7
(P = 0.317)
Low
Abnormal Involuntary Movement Scale
(worsening)
6 4 88/534 56/265 0.694 (0.521, 0.924)Footnote * –0.047 (–0.130, 0.037) 21B (8B, 27H) I 2 = 0%; χ2 = 2.6
(P = 0.460)
Low
Barnes Akathisia Rating Scale (worsening) 2–6 7 67/973 49/643 0.866 (0.609, 1.234) –0.005 (–0.030, 0.020) 200B (33B, 50H) I 2 = 0%; χ2 = 3.5
(P = 0.745)
Low
Needing medication for extrapyramidal
side-effects
2–6 9 97/1071 65/698 0.838 (0.597, 1.176) 0.004 (–0.025, 0.032) 250H (40B, 31H) I 2 = 12%; χ2 = 9.1
(P = 0.334)
Moderate
Mean weight change, kg 2–12 12 1410 948 0.640
(0.428, 0.852)Footnote *
1.753
(1.104, 2.402)Footnote *
I 2 = 83%; χ2 = 65.4
(P < 0.001)
Very low
Significant weight-gain (≥7% or recorded
as adverse effect)
2–12 10 140/1220 32/863 2.988 (2.048, 4.362)Footnote * 0.076 (0.044, 0.109)Footnote * 13H (23H, 9H)Footnote * I 2 = 0%; χ2 = 6.9
(P = 0.648)
Moderate
Sedation or somnolence 2–12 12 247/1419 57/958 2.818 (1.963, 4.047)Footnote * 0.115 (0.078, 0.151)Footnote * 9H (7H, 13H)Footnote * I 2 = 31%; χ2 = 16.1
(P = 0.138)
Moderate
Leaving early owing to adverse effects 2–12 11 97/1263 74/885 1.009 (0.753, 1.351) 0.010 (−0.010, 0.031) 100H (100B, 32H) I 2 = 0%; χ2 = 9.4
(P = 0.495)
Moderate

GRADE, Grading of Recommendations Assessment, Development and Evaluation; NNTB/H, number needed to treat (benefit/harm); RR, risk ratio.

* P < 0.05.

Fig. 4 Mean weight gain, kg. PLA, placebo; QUE, quetiapine. *Severe attrition (≥50%).

Fig. 5 Relative risk of clinically significant weight gain (normally ≥7% increase). PLA, placebo; QUE, quetiapine. *Severe attrition (≥50%).

Fig. 6 Relative risk of somnolence or sedation. PLA, placebo; QUE, quetiapine. *Severe attrition (≥50%).

Discussion

Using published and unpublished data, we found the average change in PANSS total score attributable to quetiapine IR over 2–12 weeks to be small. Although the 95% confidence intervals excluded the minimum clinically important difference of 11–15 points, it should be noted that few treatments for psychosis reach this threshold. Reference Leucht, Cipriani, Spineli, Mavridis, Orey and Richter19 Furthermore, as study duration increased, so did the effect size. Marginal advantages were observed at 2 weeks, whereas moderate effects that approached the threshold for change of at least minimal clinical importance were observed in two as yet unpublished 12-week trials. On the other hand, the overall effect size was smaller if we assumed that the substantial number of participants who left early would have had the same degree of change as placebo-treated participants who stayed. There was no evidence to suggest that drug-attributable benefits had been underestimated because of the severe rates of withdrawal in the older studies. Approximately 21 people needed to take quetiapine IR for 1 person to experience much improvement, defined in accordance with recent recommendations as a 50% or greater reduction in PANSS total score. Reference Leucht, Davis, Engel, Kissling and Kane27

Null to small effects were observed for depression and negative symptoms respectively. Although moderate effects on positive symptoms were observed in the two unpublished 12-week trials, the pooled effect over 2–12 weeks was small. The two 12-week trials also reported small to moderate effects on functioning but found no difference between quetiapine IR and placebo on participant-reported quality of life. Quetiapine IR caused weight gain and sedation, but did not lead to extrapyramidal side-effects. Although there was no evidence of increased serious adverse effects, the evidence was very low quality owing to imprecision and incomplete reporting.

We found some evidence that estimates of clinically significant response derived from more recent trials were lower than in older trials, which is consistent with results from other antipsychotic meta-analyses, Reference Leucht, Arbter, Engel, Kissling and Davis4,Reference Agid, Siu, Potkin, Kapur, Watsky and Vanderburg46 although no relationship between publication year and total symptoms was observed. It remains unclear whether reduced antipsychotic response in recent, large multisite trials with multiple treatment arms reflects a change in the characteristics of participants taking part, improvements in study quality or reporting, increased variability due to an increasing number of sites, Reference Leucht, Heres and Davis47 or better masking of treatment allocation due to reduced expectation of receiving placebo in such trials. Reference Mallinckrodt, Zhang, Prucka and Millen48

Older reviews of quetiapine IR have reported effect sizes of around 0.4 when compared with placebo, Reference Srisurapanont, Maneeton and Maneeton3,Reference Leucht, Arbter, Engel, Kissling and Davis4,Reference Leucht, Cipriani, Spineli, Mavridis, Orey and Richter19 and NNTs of around 10 or 11. Reference Srisurapanont, Maneeton and Maneeton3,Reference Leucht, Arbter, Engel, Kissling and Davis4 However, most of the trials available at the time had high rates of participant withdrawal and examined quetiapine IR as a target drug for regulatory approval rather than as a control for other preparations. Previous reviews have not been able to account for selective reporting in relation to response rates, examine the impact of changing assumptions about missing data on estimates, or consider the clinical significance of the change attributable to quetiapine IR. A more recent review pooled 4–12 week outcome data for quetiapine IR with outcome data for the more recent extended release version of quetiapine (quetiapine XR) and reported an overall moderate effect size of 0.44. Reference Leucht, Cipriani, Spineli, Mavridis, Orey and Richter19 Since quetiapine XR was judged by its manufacturer to be sufficiently novel to warrant a separate patent application and significantly greater cost, our a priori view was that pooling the data for the two formulations would give an inaccurate appraisal of both. In relation to duration, we planned to include 2-week quetiapine IR data in our review because this was the approach favoured by preceding reviews that were available at the time of protocol writing. Reference Leucht, Arbter, Engel, Kissling and Davis4 We adhered to this decision because several prescribing guidelines recommend a minimum 2-week trial, and evidence on prescribing practices suggests psychiatrists normally wait only 3–3.5 weeks before switching to another antipsychotic because of non-response. Reference Hamann, Kissling and Leucht49 Nonetheless, it is important to consider that overall efficacy was positively associated with trial duration in our review, and might have been larger still had we included quetiapine XR data. Our data may help explain why a recent meta-analysis found that quetiapine IR was significantly less effective at reducing positive symptoms than first-generation antipsychotics (nine RCTs). Reference Leucht, Corves, Arbter, Engel, Li and Davis17 In an unpublished study therapeutic dose quetiapine IR was significantly less effective than haloperidol in preventing relapse. Reference Arvanitis and Scott32

Missing data

Levels of missing data were high in the included trials. In order to reduce this, trial researchers should continue to assess participants who stop treatment early, as this will inform realistic estimates of likely outcome had they stayed, both in relation to efficacy and adverse effects. Since many early studies of other second-generation antipsychotics also suffered from severe attrition, Reference Hutton, Morrison, Yung, Taylor, French and Dunn6 the robustness of their effects to changing assumptions about missing data may also need to be examined. Although meta-regression has been used to examine the relationship between withdrawals and effect size, Reference Leucht, Cipriani, Spineli, Mavridis, Orey and Richter19 such analyses are inevitably limited by the fact that few trials have low rates of missing data. Reference Hutton, Morrison, Yung, Taylor, French and Dunn6 Application of the Ebrahim approach would help prescribers and patients appreciate the extent of uncertainty in estimates of antipsychotic benefits and costs. Reference Ebrahim, Akl, Mustafa, Sun, Walter and Heels-Ansdell13 In addition to attrition bias, the proper assessment of both drug and non-drug treatments for psychosis continues to be limited by incomplete and selective reporting of outcomes, low external validity and non-publication of negative trials. Reference Leucht, Heres, Hamann and Kane8 Indeed, a recent meta-analysis found the median effect of currently available antipsychotics over placebo fell from moderate to small after adjusting for the tendency for small studies to report larger effects, Reference Leucht, Cipriani, Spineli, Mavridis, Orey and Richter19 and selective reporting bias is a particular concern when, as documented by Spielmans & Parry and others, Reference Spielmans and Parry35 it biases our understanding of the severity of adverse effects.

Study limitations

We took advantage of several important developments in methodology which were published after we registered our protocol. Reference Ebrahim, Akl, Mustafa, Sun, Walter and Heels-Ansdell13,Reference Leucht, Rothe, Davis and Engel20,Reference Samara, Spineli, Furukawa, Engel, Davis and Salanti28 Changes post hoc do raise a risk of bias, but we had to balance this against taking the opportunity to increase the quality, robustness and usefulness of our estimates, and we hope we have provided enough information for readers to judge the merit of these decisions. Our claim that a score of 11–15 points is required for minimal clinical improvement might be controversial, not least because few treatments achieve such change in psychosis. Reference Leucht, Cipriani, Spineli, Mavridis, Orey and Richter19 However, we note the evidence supporting this minimum threshold is now quite consistent across different populations, Reference Leucht, Kane, Etschel, Kissling, Hamann and Engel10Reference Hermes, Sokoloff, Stroup and Rosenheck12 and we demonstrated that quetiapine trial researchers designed their trials to be able to detect with adequate power only differences of approximately 12 points. Although it has been argued that small benefits might have value at a public health level, Reference Leucht, Arbter, Engel, Kissling and Davis4 there is clearly a need for further debate on this issue. As with non-inferiority and equivalence trials, Reference Treadwell, Uhl, Tipton, Shamliyan, Viswanathan and Berkman34 researchers planning superiority trials might consider stating in advance what they believe constitutes a minimum important difference on continuous outcomes. Although this can be inferred from power calculations, it needs to be stated explicitly.

We were unable to access the full clinical study reports for each trial, which is problematic given a recent study found a much better quality of reporting in these documents when compared with registry reports or peer-reviewed publications. Reference Wieseler, Kerekes, Vervoelgyi, McGauran and Kaiser50 Although we have acquired a large amount of previously unpublished data, access to the reports would have raised the quality of many of the outcomes, in particular the assessments of mean weight gain and response rates. Acquiring unpublished data was challenging, and we doubt we would have been successful had a public debate on publication bias in clinical trials not been taking place at the time. This is an unsatisfactory and unsustainable situation, and a change in the law is clearly required to ensure that all trials past and present are registered, and their full methods and summary results reported, as advocated by the Alltrials campaign (www.alltrials.net).

Funding

This work was not funded. P.H. has been a co-investigator on a National Institute of Health Research (NIHR) funded pilot trial of cognitive therapy for people with psychosis who refuse antipsychotics, and is a co-investigator on another NIHR-funded pilot trial of cognitive therapy v. antipsychotics in early psychosis; J.M. is co-chairperson of the Critical Psychiatry Network.

Acknowledgements

We thank the following individuals and their organisations for providing us with unpublished data from various clinical trials: Dr Carla Canuso from Johnson & Johnson, Rakesh Kantaria, John Ramsey, Jasmine Lichfield and Craig Shering from AstraZeneca and Mads Kronborg and Dr Andrew Roberts from Lundbeck. We also thank Giovana Pezzi from AstraZeneca, Jan Yonge and Dr Chris Bushe from Eli Lilly, Sanofi (Medical Information), the UK Medicines and Healthcare Regulatory Authority, the Danish Medicines Agency, Dr Ben Goldacre, Edd Howard and Kerry Roberts.

Footnotes

Declaration of interest

None.

References

1 National Prescribing Centre. Schizophrenia Data Focussed Commentary. NPC, 2010 (http://www.npc.nhs.uk/therapeutics/cns/schizophrenia/resources/dfc_schizophrenia.pdf).Google Scholar
2 Medicines and Healthcare Products Regulatory Authority. UKPAR Seroquel XL 50mg, 200mg, 300mg & 400mg prolonged-release tablets. MHRA, 2008.Google Scholar
3 Srisurapanont, M, Maneeton, B, Maneeton, N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004; 2: CD000967.Google Scholar
4 Leucht, S, Arbter, D, Engel, RR, Kissling, W, Davis, JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009; 14: 429–47.CrossRefGoogle ScholarPubMed
5 Hamer, RM, Simpson, PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry 2009; 166: 639–41.Google Scholar
6 Hutton, P, Morrison, AP, Yung, AR, Taylor, PJ, French, P, Dunn, G. Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. Acta Psychiatr Scand 2012; 126: 111.CrossRefGoogle ScholarPubMed
7 Xia, J, Adams, C, Bhagat, N, Bhagat, V, Bhoopathi, P, El-Sayeh, H, et al. Losing participants before the end of the trial erodes credibility of findings. Psychiatr Bull 2009; 33: 254–7.Google Scholar
8 Leucht, S, Heres, S, Hamann, J, Kane, JM. Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008; 34: 275–85.Google Scholar
9 Rabinowitz, J, Davidov, O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 2008; 34: 286–91.Google ScholarPubMed
10 Leucht, S, Kane, JM, Etschel, E, Kissling, W, Hamann, J, Engel, RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006; 31: 2318–25.Google Scholar
11 Thwin, SS, Hermes, E, Lew, R, Barnett, P, Liang, M, Valley, D, et al. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures. Psychiatry Res 2013; 209: 291–6.Google Scholar
12 Hermes, ED, Sokoloff, D, Stroup, TS, Rosenheck, RA. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry 2012; 73: 526–32.CrossRefGoogle ScholarPubMed
13 Ebrahim, S, Akl, EA, Mustafa, RA, Sun, X, Walter, SD, Heels-Ansdell, D, et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. J Clin Epidemiol 2013; 66: 1014–21, e1.Google Scholar
14 Leucht, S, Kane, JM, Kissling, W, Hamann, J, Etschel, E, Engel, RR. What does the PANSS mean? Schizophr Res 2005; 79: 231–8.CrossRefGoogle ScholarPubMed
15 Furukawa, TA, Cipriani, A, Barbui, C, Brambilla, P, Watanabe, N. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 2005; 20: 4952.CrossRefGoogle ScholarPubMed
16 Higgins, JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration, 2011.Google Scholar
17 Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 3141.Google Scholar
18 Gardner, DM, Murphy, AL, O'Donnell, H, Centorrino, F, Baldessarini, RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686–93.Google Scholar
19 Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951–62.Google Scholar
20 Leucht, S, Rothe, P, Davis, JM, Engel, RR. Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol 2013; 23: 956–9.Google Scholar
21 National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary Care and Secondary Care (Update). NICE, 2009.Google Scholar
22 Bagnall, AM, Jones, L, Ginnelly, L, Lewis, R, Glanville, J, Gilbody, S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003; 7: 1193.Google Scholar
23 Jaeschke, R, Singer, J, Guyatt, GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407–15.Google Scholar
24 Schennach-Wolff, R, Obermeier, M, Seemuller, F, Jager, M, Schmauss, M, Laux, G, et al. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. J Clin Psychopharmacol 2010; 30: 726–31.Google Scholar
25 Man-Son-Hing, M, Laupacis, A, O'Rourke, K, Molnar, FJ, Mahon, J, Chan, KB, et al. Determination of the clinical importance of study results. J Gen Intern Med 2002; 17: 469–76.CrossRefGoogle ScholarPubMed
26 Guyatt, GH, Oxman, AD, Vist, GE, Kunz, R, Falck-Ytter, Y, Alonso-Coello, P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–6.Google Scholar
27 Leucht, S, Davis, JM, Engel, RR, Kissling, W, Kane, JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009; 438: 714.Google Scholar
28 Samara, MT, Spineli, LM, Furukawa, TA, Engel, RR, Davis, JM, Salanti, G, et al. Imputation of response rates from means and standard deviations in schizophrenia. Schizophr Res 2013; 151: 209–14.Google Scholar
29 Harbord, RM, Higgins, JPT. Meta-regression in STATA. Stata J 2008; 8: 493519.Google Scholar
30 Lundbeck. Synopsis – Study 11915A: a one-year multi-national, multi-centre, randomised, double-blind, parallel-group, fixed-dose bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. Lundbeck, 2010.Google Scholar
31 Lundbeck. Synopsis – Study 11916A: a one-year multi-national, multi-centre, randomised, double-blind, parallel-group, fixed-dose bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. Lundbeck, 2010.Google Scholar
32 Arvanitis, L, Scott, M. A multicenter, double blind, randomized, controlled, multiple fixed dose and dose regimen comparison of SEROQUELTM (ICI 204,636) and haloperidol in the prevention of psychotic relapse in outpatients with chronic or subchronic schizophrenia (5077IL/0015). AstraZeneca,1996.Google Scholar
33 Perlis, RH, Ostacher, M, Fava, M, Nierenberg, AA, Sachs, GS, Rosenbaum, JF. Assuring that double-blind is blind. Am J Psychiatry 2010; 167: 250–2.Google Scholar
34 Treadwell, JR, Uhl, S, Tipton, K, Shamliyan, T, Viswanathan, M, Berkman, ND, et al. Assessing equivalence and noninferiority. J Clin Epidemiol 2012; 65: 1144–9.Google Scholar
35 Spielmans, GI, Parry, PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. J Bioeth Inq 2010; 7: 1329.Google Scholar
36 Potkin, SG, Gharabawi, GM, Greenspan, AJ, Mahmoud, R, Kosik-Gonzalez, C, Rupnow, MF, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006; 85: 254–65.CrossRefGoogle ScholarPubMed
37 Canuso, CM, Dirks, B, Carothers, J, Kosik-Gonzalez, C, Bossie, CA, Zhu, Y, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009; 166: 691701.CrossRefGoogle ScholarPubMed
38 Arvanitis, LA, Miller, BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233–46.Google Scholar
39 Lindenmayer, JP, Brown, D, Liu, S, Brecher, M, Meulien, D. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull 2008; 41: 1135.Google ScholarPubMed
40 Findling, RL, McKenna, K, Earley, WR, Stankowski, J, Pathak, S. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2012; 22: 327–42.Google Scholar
41 Small, JG, Hirsch, SR, Arvanitis, LA, Miller, BG, Link, CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549–57.CrossRefGoogle ScholarPubMed
42 Borison, RL, Arvanitis, LA, Miller, BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16: 158–69.Google Scholar
43 Kahn, RS, Schulz, SC, Palazov, VD, Reyes, EB, Brecher, M, Svensson, O, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 832–42.Google Scholar
44 Cutler, AJ, Tran-Johnson, T, Kalali, A, Astrom, M, Brecher, M, Meulien, D. A failed 6-week, randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. Psychopharmacol Bull 2010; 43: 3769.Google Scholar
45 Chen, EY, Hui, CL, Lam, MM, Chiu, CP, Law, CW, Chung, DW, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010; 341: c4024.Google Scholar
46 Agid, O, Siu, CO, Potkin, SG, Kapur, S, Watsky, E, Vanderburg, D, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970–2010. Am J Psychiatry 2013; 170: 1335–44.Google Scholar
47 Leucht, S, Heres, S, Davis, JM. Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle. Am J Psychiatry 2013; 170: 1232–4.Google Scholar
48 Mallinckrodt, CH, Zhang, L, Prucka, WR, Millen, BA. Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull 2010; 43: 5372.Google Scholar
49 Hamann, J, Kissling, W, Leucht, S. How long do psychiatrists wait for response before they switch to another antipsychotic? Psychopharmacol Bull 2007; 40: 149–54.Google Scholar
50 Wieseler, B, Kerekes, MF, Vervoelgyi, V, McGauran, N, Kaiser, T. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ 2012; 344: d8141.Google Scholar
51 Hough, DW, Natarajan, J, Vandebosch, A, Rossenu, S, Kramer, M, Eerdekens, M. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2011; 26: 2534.Google Scholar
52 Chapel, S, Hutmacher, MM, Haig, G, Bockbrader, H, de Greef, R, Preskorn, SH, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009; 49: 1297–308.Google Scholar
Figure 0

Fig. 1 Study search procedure. IR, immediate release; RCT, randomised controlled trial.

Figure 1

Table 1 Included studies and Cochrane risk of bias ratings

Figure 2

Table 2 Primary efficacy outcomes

Figure 3

Fig. 2 Mean change in Positive and Negative Syndrome Scale (PANSS) total scores or equivalent, using mostly original last observation carried forward estimates to impute missing data. PLA, placebo; QUE, quetiapine. *Severe attrition (≥50%).

Figure 4

Fig. 3 Relative risk of not achieving at least 50% reduction in Positive and Negative Syndrome Scale (PANSS) total scores or equivalent, based mostly on last observation carried forward data; F estimated using Furukawa method. PLA, placebo; QUE, quetiapine. *Severe attrition (≥50%).

Figure 5

Table 3 Main safety outcomes

Figure 6

Fig. 4 Mean weight gain, kg. PLA, placebo; QUE, quetiapine. *Severe attrition (≥50%).

Figure 7

Fig. 5 Relative risk of clinically significant weight gain (normally ≥7% increase). PLA, placebo; QUE, quetiapine. *Severe attrition (≥50%).

Figure 8

Fig. 6 Relative risk of somnolence or sedation. PLA, placebo; QUE, quetiapine. *Severe attrition (≥50%).

Supplementary material: PDF

Hutton et al. supplementary material

Supplementary Material

Download Hutton et al. supplementary material(PDF)
PDF 746.3 KB
Submit a response

eLetters

No eLetters have been published for this article.